

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date:	Monday, December 15, 2025
Time:	12:00 pm Eastern Time
Location:	Zoom Teleconference
Institution:	Retina Vitreous Associates of Florida, Largo, FL
Principal Investigator:	David A. Eichenbaum, MD
Protocol:	AbbVie, Inc., RGX-314-3101
NCT Number:	NCT05407636
Meeting Type:	Continuing Review of Protocol and Site
Title:	A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

1. Call to order:

The Meeting was called to order at 12:06 pm Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Four voting members were present, including two local members unaffiliated with the institution. Also present were IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

An Institutional Representative was not present and could not confirm that notice of the meeting was publicly posted.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 4 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair provided an overview of changes since the last review

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-1 containment facilities and practices plus Standard Precautions** are required for ABBV-RGX-314, since it consists of an adeno-associated viral (AAV) vector administered by injection in a clinical setting. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of ABBV-RGX-314 locally**, provided that other biosafety criteria for study closure are also met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 4 NO: 0 ABSTAIN: 0

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

1. The Committee recommended that “RGX-314” be replaced with “ABBV-RGX-314” where applicable in the Biosafety SOP and Biohazard Sign as the name of the study agent has changed.
2. The Committee recommended that the institution confirm whether eyewash bottles are available in the study agent handling areas in [REDACTED]
3. The Committee discussed posted biohazard signage at the entrance to the study agent storage room and recommended that the Institution submit a photo of the posted signage to IBC Services.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 4

NO: 0

ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 12:14 pm Eastern Time.